|
Correlation of the immune tumor microenvironment (I-TME) with gene expression profiles as prognostic and predictive factors in patients (pts) with metastatic renal carcinoma (mRCC) treated with immunotherapy (Meet-URO 18 I-TME study). |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; MSD |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; MSD |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - BMS; BMS; Ipsen; Merck/Pfizer; MSD; Pfizer; Pfizer |
Speakers' Bureau - BMS; Ipsen; Merck/Pfizer; MSD; Pfizer |
Research Funding - Novartis (Inst); Pfizer (Inst) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Bristol-Myers Squibb; ipsen; Janssen Oncology; Merck/Pfizer; MSD Oncology |
Other Relationship - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Merck/Pfizer; MSD |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca; MSD Italy |
Travel, Accommodations, Expenses - AstraZeneca |